|
Adult Lymphoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Our findings showed BMI, and BMI in early adulthood (aged 18-21 years) is associated with the risk of Hodgkin's and non-Hodgkin's lymphoma (HL and NHL), diffuse large beta-cell lymphoma (DLBCL), Leukaemia including acute and chronic myeloid lymphoma (AML and CML), and chronic lymphocytic leukaemia (CLL) and multiple myeloma (MM).
|
30753270 |
2019 |
|
Adult Lymphoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
We have demonstrated that IFN-free DAA treatment of HCV can improve or even cure NHL. miRNA-26b-levels could be a potentially useful biomarker to predict lymphoma response in HCV-NHL patients.
|
31180334 |
2019 |
|
Adult Lymphoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Despite the classic approach "solid cancer first", due to the advanced stage of lymphoma we first started the chemotherapy of NHL.
|
29419687 |
2018 |
|
Adult Lymphoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Results A total of 140 patients with various types of B-NHL, including 74% with diffuse large Bcell lymphoma, were analysed.
|
28144804 |
2017 |
|
Adult Lymphoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Integrating these findings is important for constructing comprehensive models of NHL pathogenesis, which could yield novel targets for therapy and strategies for lymphoma prevention in certain populations.
|
27115168 |
2016 |
|
Adult Lymphoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
In this study, we carried out a CNV analysis using GWAS data from 681 NHL cases and 749 controls to explore the relationship between common structural variation and lymphoma susceptibility.
|
25133503 |
2014 |
|
Adult Lymphoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Genotype distributions were studied in 213 lymphoma Caucasian patients (193 non-Hodgkin/NHL and 20 Hodgkin lymphoma/HL) and 214 controls, residents in a region of Southeast Spain.
|
23818366 |
2013 |
|
Adult Lymphoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
We used a panel of 193 formalin fixed tissues of lymphoma cases consisting of 55 cases of HL and 138 cases on several B-NHL entities.
|
22672495 |
2012 |
|
Adult Lymphoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Treatment of patients with relapsed or refractory low grade follicular B-NHL lymphoma with rituximab (chimeric anti-CD20 mAb) has resulted in approximately 50% response rate.
|
19885551 |
2009 |
|
Adult Lymphoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
These results indicate that in vitro chemosensitivity testing and gene expression profiling can successfully be utilised to analyse in vivo drug response in patients with leukemic NHL's and can be used to explore new pathway models of drug-induced cell death in vivo which are independent of different lymphoma subtypes and different treatment regimens.
|
16213748 |
2006 |
|
Adult Lymphoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Results showed a clear difference in TGF 1 expression in patients with NHL depending on the subtype of the lymphoma, suggesting its significant role in the pathomechanism of this group of malignant diseases as well as its potential value as a prognostic factor.
|
14704634 |
2004 |
|
Adult Lymphoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
In this article, we will demonstrate that the plasmatic level of soluble HLA-G was significantly increased in 70% of B chronic lymphocytic leukemia, 53% of non-Hodgkin B lymphoma (B-NHL), and 45% of T-NHL.
|
14602240 |
2003 |
|
Adult Lymphoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Of the 13, 7 were NHL and 1 was a myeloma which progressed to lymphoma.
|
1829873 |
1991 |